What is Mounjaro? GLP-1/GIP Obesity Medication Information Often Searched as Pounjaro

Names such as “Wegovy” and “Mounjaro” have been appearing frequently lately. These are prescription GLP-1-class medicines originally developed for diabetes and obesity treatment, and some have drawn attention because of their weight-loss effects. However, these medicines are not casual diet supplements you can simply buy and take; they require a doctor’s diagnosis and prescription. This article focuses on “Mounjaro (tirzepatide)” and summarizes what kind of medicine it is and what precautions matter.

What kind of medicine is Mounjaro?

Mounjaro, whose active ingredient is tirzepatide, is a once-weekly subcutaneous injection developed by Eli Lilly. In Korea, it was approved and launched as a treatment for type 2 diabetes in 2024~2025. In the United States, the same ingredient is also used under a separate brand name, “Zepbound,” for the obesity or weight-management indication. In other words, even with the same active ingredient, the product name and approved scope may differ depending on the country and indication.

What does GIP/GLP-1 “dual action” mean?

When we eat, the body secretes gut hormones called incretins to regulate blood sugar and appetite. Two representative examples are GLP-1 and GIP. Existing medicines such as Wegovy and Ozempic act on a single GLP-1 pathway, while tirzepatide is characterized by being designed to act on both GLP-1 and GIP receptors at the same time. This “dual action” structure distinguishes it from other medicines because its mechanism is not limited to one pathway.

How weight loss happens

There are two main mechanisms by which this class of medicines affects body weight. First, they act on the brain’s appetite center to reduce feelings of hunger. Second, they slow the speed at which food leaves the stomach, known as gastric emptying, helping fullness last longer. As a result, total food intake decreases; these medicines do not directly “burn” fat.

How is it different from Wegovy, Ozempic, and Saxenda?

• Wegovy and Ozempic: the active ingredient is semaglutide from Novo Nordisk, with single GLP-1 action. Wegovy was launched in Korea in 2024 for obesity treatment and is a once-weekly subcutaneous injection.
• Saxenda: another GLP-1 medicine line from Novo Nordisk.
• Mounjaro: the active ingredient is tirzepatide from Eli Lilly, with dual GIP+GLP-1 action and once-weekly injection. In Korea, it was launched for the diabetes indication.
• In short, the manufacturer, active ingredient, number of hormone pathways involved, and approved indication in Korea differ. Which medicine is appropriate for an individual depends on the patient’s condition and should be judged by a doctor.

Has an “oral GLP-1 obesity medicine” been released?

People who find injections burdensome often show interest in oral GLP-1 medicines. Eli Lilly’s orforglipron is known as an oral candidate that has completed phase 3 clinical trials and is in the approval and review stage. However, this is still a development and approval-stage outlook, before general launch. Specific launch timing, price, and domestic brand name have not been finalized and may change, so related information should be checked through the latest official announcements and news whenever possible. If you see online claims that a product under a particular name has “already been released,” check whether they are true.

Common side effects and risks to watch for

• The most common side effects are gastrointestinal symptoms: nausea, vomiting, diarrhea, constipation, and similar issues. They tend to appear more often early on when the dose is being increased.
• Rarely, pancreatitis and gallstones have been reported. If severe abdominal pain persists, medical care is needed immediately.
• Boxed warning, the strongest warning: because thyroid C-cell tumors were observed in animal, specifically rodent, studies, the medicine is contraindicated for people with a personal or family history of medullary thyroid carcinoma or a history of multiple endocrine neoplasia syndrome type 2, known as MEN2.
• Other reactions can vary by individual, so if unusual symptoms occur, do not judge them on your own; consult medical professionals.

Essential fact: this is a prescription medicine

1. These medicines are not diet supplements but prescription drugs, and they are prescribed at a doctor’s discretion when indications such as BMI criteria are met.
2. Misuse for cosmetic or simple weight-loss purposes, direct overseas purchasing, or using someone else’s medicine on your own is risky from both safety and legal perspectives.
3. After stopping the medicine, appetite may return and weight may increase again, a rebound that has been reported. Lifestyle management such as diet and exercise needs to accompany treatment.
4. If prescribed without insurance coverage, the cost can be quite high, and coverage status and price vary depending on timing and indication.

Important notice and disclaimer

This article is for general medical information only and does not replace diagnosis or prescription. Whether the medicine is appropriate, and whether to start, stop, or change the dose, should be decided in consultation with a doctor or pharmacist whenever possible. Indications, approved scope, insurance coverage, and prices can vary by time and country, so check the latest information through official sources such as the Ministry of Food and Drug Safety and through medical consultation. If emergency symptoms such as severe abdominal pain, difficulty breathing, or an allergic reaction are suspected, visit a medical institution immediately.